IN2012DN02869A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02869A IN2012DN02869A IN2869DEN2012A IN2012DN02869A IN 2012DN02869 A IN2012DN02869 A IN 2012DN02869A IN 2869DEN2012 A IN2869DEN2012 A IN 2869DEN2012A IN 2012DN02869 A IN2012DN02869 A IN 2012DN02869A
- Authority
- IN
- India
- Prior art keywords
- peptide
- specifically
- humanized antibodies
- antibodies
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 101000944608 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Chaperonin GroEL 2 Proteins 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24021809P | 2009-09-06 | 2009-09-06 | |
| PCT/IL2010/000731 WO2011027349A1 (en) | 2009-09-06 | 2010-09-06 | Humanized antibodies specific for hsp65-derived peptide-6 methods and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02869A true IN2012DN02869A (enExample) | 2015-07-24 |
Family
ID=43648941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2869DEN2012 IN2012DN02869A (enExample) | 2009-09-06 | 2010-09-06 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8680241B2 (enExample) |
| EP (2) | EP3366308A1 (enExample) |
| JP (1) | JP5781514B2 (enExample) |
| KR (1) | KR101831229B1 (enExample) |
| CN (1) | CN102740877B (enExample) |
| AU (1) | AU2010290844B2 (enExample) |
| BR (1) | BR112012004983A2 (enExample) |
| CA (1) | CA2772567A1 (enExample) |
| IN (1) | IN2012DN02869A (enExample) |
| MX (1) | MX2012002768A (enExample) |
| RU (1) | RU2596925C2 (enExample) |
| WO (1) | WO2011027349A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007284690A1 (en) | 2006-08-10 | 2008-02-21 | Roy C. Levitt | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
| BR112017005451A2 (pt) * | 2014-10-24 | 2018-01-02 | Hoffmann La Roche | anticorpo humanizado e métodos para a seleção de um ou mais fragmentos fv de anticorpo variantes e para a produção de um anticorpo |
| WO2016116948A1 (en) | 2015-01-22 | 2016-07-28 | Ram Isanaka | Peptide for treating inflammatory diseases |
| ES2965292T3 (es) * | 2015-07-09 | 2024-04-12 | Inst Nat Sante Rech Med | Vector lentiviral que expresa anticuerpo anclado a membrana o secretado |
| US12296085B2 (en) * | 2016-03-31 | 2025-05-13 | ImMutriX Therapeutics, Inc. | Method for extracorporeal treatment of preeclampsia and related disorders |
| EP4650007A2 (en) * | 2018-08-01 | 2025-11-19 | Imcheck Therapeutics | Anti-btn3a antibodies and their use in treating cancer or infectious disorders |
| WO2025155809A2 (en) * | 2024-01-18 | 2025-07-24 | Nextcure, Inc. | Compositions and methods for modulating vstm-1 mediated signal transduction |
| WO2025231127A1 (en) * | 2024-05-02 | 2025-11-06 | The Regents Of The University Of California | Compositions and methods for intracellular antigen targeting with antibodies |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9125979D0 (en) * | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
| DK1127064T3 (da) * | 1998-11-05 | 2006-05-22 | Hadasit Med Res Service | Hidtil ukendte aminosyresekvenser, DNA, der koder for aminosyresekvenserme, antistoffer, der er rettet mod sådanne sekvenser, og forskellige anvendelser deraf |
| US7488476B2 (en) * | 1998-11-05 | 2009-02-10 | Hadasit Medical Research Services & Development Ltd. | B-cell epitope peptides of HSP 65, DNA encoding said peptides, antibodies directed against said peptides and the different uses thereof in the treatment of inflammatory and autoimmune diseases |
| WO2003057527A2 (en) * | 2001-12-31 | 2003-07-17 | L.A.S. Trust, Ein 02/6105365 | Recreational vehicle |
| EP1619521A1 (en) | 2004-07-22 | 2006-01-25 | IEE INTERNATIONAL ELECTRONICS & ENGINEERING S.A. | Capacitive transmitter electrode |
| CU23504A1 (es) * | 2004-09-24 | 2010-04-13 | Ct Ingenieria Genetica Biotech | Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas |
| JP2008528668A (ja) | 2005-02-03 | 2008-07-31 | アンチトープ リミテッド | ヒト抗体及びタンパク質 |
| EP1928497A2 (en) * | 2005-08-24 | 2008-06-11 | Cell-Matrix, Inc. | Combination therapies for inhibiting integrin-extracellular matrix interactions |
| JP5161798B2 (ja) | 2006-03-02 | 2013-03-13 | アンチトープ リミテッド | Ｔ細胞アッセイ |
| EP2032162A2 (en) * | 2006-05-22 | 2009-03-11 | Board of Regents, The University of Texas System | Herv-k antigens, antibodies, and methods |
| WO2008114733A1 (ja) | 2007-03-16 | 2008-09-25 | Kyowa Hakko Kirin Co., Ltd. | 抗Claudin-4抗体 |
| EP2220122A2 (en) * | 2007-11-13 | 2010-08-25 | Teva Biopharmaceuticals USA, Inc. | Humanized antibodies against tl1a |
| EP2414397A1 (en) | 2009-03-30 | 2012-02-08 | Protab Ltd. | Adenylyl cyclase-associated protein (cap1) and uses thereof as a target for immuno-modulation |
| CA2841416A1 (en) * | 2011-06-15 | 2012-12-20 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of selecting therapeutic indications |
-
2010
- 2010-09-06 MX MX2012002768A patent/MX2012002768A/es not_active Application Discontinuation
- 2010-09-06 BR BR112012004983-6A patent/BR112012004983A2/pt not_active Application Discontinuation
- 2010-09-06 WO PCT/IL2010/000731 patent/WO2011027349A1/en not_active Ceased
- 2010-09-06 JP JP2012527448A patent/JP5781514B2/ja not_active Expired - Fee Related
- 2010-09-06 IN IN2869DEN2012 patent/IN2012DN02869A/en unknown
- 2010-09-06 US US13/392,548 patent/US8680241B2/en not_active Expired - Fee Related
- 2010-09-06 EP EP18161381.1A patent/EP3366308A1/en not_active Withdrawn
- 2010-09-06 KR KR1020127008389A patent/KR101831229B1/ko not_active Expired - Fee Related
- 2010-09-06 CA CA2772567A patent/CA2772567A1/en not_active Abandoned
- 2010-09-06 AU AU2010290844A patent/AU2010290844B2/en not_active Ceased
- 2010-09-06 EP EP10813428.9A patent/EP2475383A4/en not_active Withdrawn
- 2010-09-06 CN CN201080050177.2A patent/CN102740877B/zh not_active Expired - Fee Related
- 2010-09-06 RU RU2012106891/10A patent/RU2596925C2/ru not_active IP Right Cessation
-
2014
- 2014-01-31 US US14/169,996 patent/US20140170138A1/en not_active Abandoned
-
2017
- 2017-04-19 US US15/491,377 patent/US20170218056A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2475383A4 (en) | 2013-07-17 |
| JP5781514B2 (ja) | 2015-09-24 |
| CN102740877B (zh) | 2015-01-14 |
| US20140170138A1 (en) | 2014-06-19 |
| JP2013503852A (ja) | 2013-02-04 |
| CA2772567A1 (en) | 2011-03-10 |
| MX2012002768A (es) | 2012-06-28 |
| US8680241B2 (en) | 2014-03-25 |
| RU2012106891A (ru) | 2013-10-27 |
| EP3366308A1 (en) | 2018-08-29 |
| BR112012004983A2 (pt) | 2021-02-23 |
| US20170218056A1 (en) | 2017-08-03 |
| EP2475383A1 (en) | 2012-07-18 |
| WO2011027349A1 (en) | 2011-03-10 |
| CN102740877A (zh) | 2012-10-17 |
| AU2010290844B2 (en) | 2015-04-09 |
| RU2596925C2 (ru) | 2016-09-10 |
| KR101831229B1 (ko) | 2018-02-22 |
| US20120156201A1 (en) | 2012-06-21 |
| AU2010290844A1 (en) | 2012-03-15 |
| KR20120060224A (ko) | 2012-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN02869A (enExample) | ||
| NZ596540A (en) | Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide | |
| NZ601793A (en) | Methods and compositions for diagnosis and treatment of cancer | |
| WO2005103083A8 (en) | Anti-cd38 human antibodies and uses therefor | |
| NZ601583A (en) | Novel rabbit antibody humanization methods and humanized rabbit antibodies | |
| NZ601615A (en) | Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor | |
| NZ593550A (en) | ANTI-Siglec-15 ANTIBODY | |
| MX2009012949A (es) | Anticuerpos humanizados que enlazan a ab (1-42) globulomero y usos de los mismos. | |
| NZ599140A (en) | Antibodies that specifically bind to the epha2 receptor | |
| UA111818C2 (uk) | Антитіло проти csf-1r | |
| MX2012000841A (es) | Optimizacion de la produccion de anticuerpos. | |
| MX2010010387A (es) | Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos. | |
| MX2009004532A (es) | Composiciones y metodos para unir esfingosina-1-fosfato. | |
| MX2011008843A (es) | Anticuerpos humanizados que se unen a cd19 y sus usos. | |
| EA201490677A1 (ru) | Связывающие антиген cd27l белки | |
| NZ612312A (en) | Her2 binding peptides labeled with aluminium-[18] fluoride complexed by nota | |
| NZ714516A (en) | Human antibodies to clostridium difficile toxins | |
| MX2010004660A (es) | NUEVOS ANTICUERPOS ESPECIFICOS DE LOS PEPTIDOS ß-AMILOIDES Y SUS USOS COMO AGENTES DE DIAGNOSTICO Y DROGAS. | |
| EP3144323A3 (en) | Anti-c4.4a antibodies and uses thereof | |
| MX340772B (es) | Medios y metodos para fabricar neurotoxina altamente pura. | |
| NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
| NZ612327A (en) | Her2 binding peptides labelled with a 18f - containing organosilicon compound | |
| MY166152A (en) | Anti-human xcr1 antibodies | |
| EP2534168A4 (en) | CHEMICAL PREPARATION OF UBIQUITINTHIOESTERN AND MODIFICATIONS THEREOF | |
| PH12012501743A1 (en) | Antigen binding proteins specific for serum amyloid p component |